I
nsulin-like growth factor-1 (IGF-1), a 70-aa polypeptide, is associated with the normal differentiation of mesenchymal tissues and the abnormal growth of animal and human tumors. [1] [2] [3] Many animal and human malignancies, such as nervous system-derived tumors and colon and liver cancer, have been reported to express high levels of IGF-1. 4 -6 The production of IGF-1 in cultured tumor cell lines is related to continuous proliferation in vitro as determined by blocking experiments with antibodies (Abs) specific for IGF-1. 7 Previous reports by us and others have shown that rat C6 glioma and PCC3 mouse teratocarcinoma cells expressing IGF-1 lose tumorigenicity and become immunogenic after transfection with an episomal expression vector producing IGF-1 antisense RNA. Immunization with the transfected tumor cells elicited a specific immune response mediated by CD8 ϩ T cells, which afforded protection against parental tumor cell challenge and cured established tumors. 8 -12 The mechanism by which the immunogenicity of tumor cells can be endowed by transfection with IGF-1 antisense vector is under investigation.
Recent studies have shown that rat C6 glioma and LFCL 2 hepatoma cells express an increased level of major histocompatibility complex (MHC) class I molecules on their cell surfaces after being transfected with IGF-1 antisense expression vector. 7 This expression is correlated closely with the poor tumorigenicity of the transfected tumor cells in syngeneic animals. However, the transfection of tumor cells with IGF-1 antisense expression vector is not uniformly effective in the induc-tion of an immune response. Some IGF-1-producing tumor cell lines, with complete block of IGF-1 production and enhanced expression of MHC class I molecules on their cell surfaces after transfection, continue to remain tumorigenic in syngeneic animals. According to current reports, both antigen (Ag)-specific and costimulatory signals are essential for the full activation of T-cell-mediated antitumoral immune responses. [13] [14] [15] [16] [17] [18] [19] The Ag-specific signal is delivered by interaction between the MHC-peptide complex on tumor cells and the T-cell receptor (TCR) on T cells. Costimulatory signals are mediated by cytokines and adhesion molecules. One well-characterized costimulatory signal is provided by the interaction between CD28 on T cells and its primary ligands B7.1 (CD80) or B7.2 (CD86) on Ag-presenting cells. 20 Absence of either MHC or costimulatory molecules on tumor cells results in a failure to induce T-cell-mediated antitumoral immunity. [21] [22] [23] Therefore, we reasoned that the lack of responsiveness of some tumor cells to the IGF-1 antisense RNA approach could be due to the absence of costimulatory signals on these transfected tumor cells. To test this hypothesis, we used hepa 1-6 hepatoma and SMCC-1 colon cancer model systems to evaluate the efficacy of cotransfection with genes encoding both IGF-1 antisense and mouse B7.1 molecules. Hepa 1-6 and SMCC-1 cell lines are derived from tumors chemically induced in C57BL/6 mice. Both grow rapidly, forming subcutaneous (s.c.) tumors. 24, 25 The lack of both MHC class I and B7 molecules on cell surfaces and the failure to induce host immune responses when transfected with genes encoding either antisense IGF-1 or the B7.1 molecule make the two cell lines unique in vivo tumor model systems, and both are well-suited for experimental immunotherapy studies. Using the double gene transfection approach, both hepa 1-6 and SMCC-1 cell lines were successfully converted from poorly immunogenic to immunogenic. The transfectants were effective in priming naive spleen T cells from syngeneic mice with the generation of tumorspecific cytotoxic T lymphocytes (CTLs) in vitro and in eliciting antitumoral immune responses in vivo.
The data presented here suggest that cotransfection with a B7.1 expression vector synergizes with the IGF-1 antisense gene transfer method to generate immunogenic tumor cells in vitro. The resulting cells could be used as cellular tumor vaccines to elicit antitumoral specific immune responses that are effective in eradicating large established tumors. Modification of autologous tumor cells by this double gene transfer approach may provide a valuable strategy for generating cellular vaccines that are effective in the treatment of cancers.
MATERIALS AND METHODS

Mice and cell lines
Female C57BL/6 mice, 6 -8 weeks of age, were purchased from The Jackson Laboratory (Bar Harbor, Me). The animals were maintained in a central core facility and allowed free access to food and water. Nude/nude and severe combined immunodeficient (SCID)/CB17 mice of 10 -12 weeks of age were obtained from the colonies maintained by the International Joint Cancer Institute and Eastern Hospital of Hepatobiliary Surgery, Second Military Medical University, and were housed under specific pathogen-free conditions as described previously. 26 Hepa 1-6, a poorly immunogenic mouse hepatoma cell line derived from C57BL/6 mice, was obtained from the American Type Culture Collection (ATCC) (Manassas, Va). Highly tumorigenic clones were established by in vivo selection and used in this study. 24 The SMCC-1 cell line was established from a chemically induced colon carcinoma originating in a C57BL/6 mouse. Cells derived from this cancer grow and form s.c. nodes in syngeneic animals. EL-4 lymphoma cells, B16 F1 melanoma cells, and a natural killer (NK) sensitive cell line (YAC-1) were purchased from ATCC and used as targets for the cytotoxicity assay. Concanavalin A-stimulated lymphoblasts were prepared as described previously. 27 All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf sera in a humidified atmosphere with 5% CO 2 at 37°C; cells were passaged twice each week.
Transfection of tumor cells and selection of stable transfectants in vitro
Hepa 1-6 and SMCC-1 cells were first transfected with antisense IGF-1 vector to inhibit IGF-1 expression as described previously. 6 -8 Briefly, PAnti-IGF-1 vector was introduced into hepa 1-6 and SMCC-1 cells by a standard electroporation protocol. Electroporated cells were then cultured in RPMI 1640 medium supplemented with 15% fetal bovine sera and 15% conditioned medium obtained from parental tumor culture supernatant. At 48 hours posttransfection, stable transfectants were selected in medium containing 800 g/mL hygromycin (Sigma, St. Louis, Mo). Hygromycin-resistant clones were then subcloned by limiting dilution and analyzed for IGF-1 expression by immunofluorescent staining. For B7.1 transfection, a DNA fragment encoding full-length murine B7.1 was amplified by polymerase chain reaction and then cloned directly into the pLXSN retroviral vector 14 (obtained from Dr. D. Miller, Fred Hutchinson Cancer Center, Seattle, Wash). Plasmid containing the murine B7.1 insert was then transfected into PA317 amphotropic packaging cells by electroporation as described previously. 27, 28 After selection in the presence of 1.5 mg/mL G418 (Life Technologies, Gaithersburg, Md), PA317 transfectants were tested for virus production. Viruses from the PA317 transfectants were then used to infect the -2 ecotropic packaging cell line in the presence of 10 g/mL polybrene (Sigma). The viruses producing the -2 cell line were maintained in 1.5 mg/mL G418 medium for 4 weeks, and the supernatant from cultured -2 cells was used to infect hepa 1-6 and SMCC-1 cells, both of which had been transfected with antisense IGF-1-expressing vector. Cell lines transfected with both antisense IGF-1-expressing vector and the recombinant retrovirus containing mouse B7.1 insert were selected and subcloned in a double selection medium consisting of 800 g/mL hygromycin and 1.5 mg/mL G418. Mock virus and episomal-based vector devoid of IGF-1 antisense cDNA were used to transfect control cell lines as described previously. 28 
Immunofluorescent staining and flow cytometry analyses
The production of IGF-1 in transfected tumor cells was determined by indirect immunofluorescent staining with polyclonal Ab against IGF-1 as described previously. [5] [6] [7] [8] Ab specific for IGF-1 was purchased from KabiGen (Stockholm, Sweden) and used at a 1/500 dilution. For detection of the expression of MHC and adhesion molecules on the transfectants that have a potential to costimulate host immune responses, the cells were washed with phosphate-buffered saline and stained with rat monoclonal Abs (mAbs) to mouse MHC class I (M1/42), MHC class II (M5/114), B7.1 (4H12), intracellular adhesion molecule-1 (ICAM-1) (HA58), ICAM-2 (3C4), vascular cell adhesion molecule-1 (51-10C9) (PharMingen, San Diego, Calif), and CD44 (KM81) (ATCC). To stain for mouse B7.1 (CD80) and B7.2 (CD86) expression, we also used CTLA-4 immunoglobulin (Ig), a soluble fusion protein containing the variable domain of the human CTLA-4 protein and the hinge CH2 and CH3 domains of the human IgG1 constant region. 29 Cells were incubated with the Abs or chimeric protein for 40 minutes on ice. A rat Ab to murine CD3 (YCD3) and a soluble human CD44-Ig fusion protein were used as negative controls. After washing three times, fluorescein isothiocyanate (FITC)-conjugated goat Ab to rat Ig or hamster Ig or FITC-labeled rabbit Ab to human Ig was added to cells for an additional 40 minutes on ice. The same procedure was used to analyze T-cell subsets using rat mAbs to CD3 (YCD3), CD4 (GK1.5), CD8 (Lyt 2), and CD25 (PC61 5.3) as described previously. 24 -27 Finally, the cells were washed, fixed, and analyzed in a FACScan (Becton Dickinson, San Jose, Calif). The mean fluorescent intensity in the negative control was used as the background level.
Comparison of tumor cell proliferation in vitro
A total of 2 ϫ 10 4 cells were plated into each well of 96-well, flat-bottom microtiter plates (Falcon, Lincoln Park, NJ) and cultured in RPMI 1640 medium supplemented with15% IGFfree fetal calf sera. IGF-1 containing medium prepared by the addition of 15% conditioned medium obtained from parental tumor culture supernatant was used as a control. After 24 hours, Cells were pulsed with 1 Ci of [ 3 H]thymidine for 4 and 12 hours; next, cells were harvested with an automatic harvester and [
3 H]thymidine incorporation was determined as described previously. 24 All cultures in these experiments were done in triplicate.
Comparison of tumor growth in vivo
To test the tumorigenicity of transfectants in both immunodeficient mice and immunocompetent mice, 1 ϫ 10 6 each of IGF-1 antisense transfectants, B7.1 transfectants, IGF-1 antisense and B7.1 cotransfectants, and mock-transduced control cells were injected s.c. into groups of nude mice, SCID mice, or C57BL/6 mice. Experiments were then repeated twice by injecting an additional five mice each with each of the different clones of transfectants. Animals were monitored weekly. Tumor size was measured using a caliper. Some mice were sacrificed at day 40 after tumor inoculation for histopathological examination; other mice were observed for 5 months.
Immunization with transfectants
For immunoprotective experiments, groups of C57BL/6 mice were injected s.c. with 1 ϫ 10 6 hepa 1-6 transfectants, SMCC-1 transfectants, or mock transfectants in a 0.2-mL volume. After 2 weeks, mice in each of the 10 groups were challenged with 1 ϫ 10 6 parental hepa 1-6 cells or parental SMCC-1 cells, respectively, in accordance with the primary immunization.
For curative experiments, mice were first injected s.c. with 2 ϫ 10 6 parental hepa 1-6 or SMCC-1 cells. After 3 weeks, these animals were treated by s.c. injection with hepa 1-6 transfectants or SMCC-1 transfectants. To determine the efficacy of irradiated transfectants in the cure of established tumors, the ␥-irradiated (5000 rad) transfectants were injected s.c. into tumor-bearing mice at a dose of 1 ϫ 10 6 cells. Tumor growth was monitored weekly and mean survival time was calculated. Tumor tissues from the treated mice were subjected to histopathological examination for a determination of local immune responses and of the phenotypes of tumor-infiltrating T cells as described previously. 8, 19 Depletion of CD4 ϩ and CD8 ϩ T-lymphocyte subsets in syngeneic animals Female C57BL/6 mice were treated with purified anti-mouse CD4 (GK1.5), or anti-CD8 (Lyt 2) or with a control mouse anti-diethylthiamine pentaacetic acid mAb. Each animal was injected with 500 g of the purified mAb (i.v.) twice per week for 3 weeks. At 2 days before the injection of tumor cells, peripheral blood lymphocytes were obtained from individually treated mice and stained with mAb to CD4 or CD8 Ag to verify the depletion of CD4 ϩ or CD8 ϩ cells. At 3 days after the final injection of mAbs, all mice were injected s.c. with 2 ϫ 10 
Cytotoxicity assay of CTLs and adoptive transfer experiments
Spleen cell suspensions were freshly isolated and prepared from 4-week-old naive C57BL/6 mice. A total of 5 ϫ 10 6 cells were plated into 24-well tissue culture plates (Costar, Cambridge, Mass) and cocultured for 9 days with 5 ϫ 10 5 ␥-irradiated (5000 rad) and DT hepa 1-6 cells, DT SMCC-1 cells, or mock-transfected (MT) control cells. A total of 5 ϫ 10 6 ␥-irradiated naive spleen cells were added into cultures as feeder cells. On days 3 and 6 after coculture, 2 mL of complete RPMI 1640 medium containing human recombinant interleukin-2 (rIL-2) (50 /mL) was added into each culture well. The cytotoxicity of CTLs generated in vitro by stimulating naive spleen cells or spleens freshly prepared from the immunized mice was determined in a standard 4-hour 51 Cr release assay. 24 For the CTL adoptive transfer experiments, 6-to 8-week-old C57BL/6 mice in groups of five each were injected s.c. with 1 ϫ 10 6 SMCC-1 or hepa 1-6 cells. After 2 weeks, 1 ϫ 10 7 CTLs generated by priming naive spleen cells in vitro with double transfectants or spleen cells obtained from mice immunized with double transfectants were injected intravenously (i.v.) into tumor-bearing mice individually. All animals were given an i.v. injection of 1000 U of rIL-2 daily for 10 days starting at day 2 after injection of CTLs. Tumor growth was monitored weekly, and survival time was calculated as described previously. 19, 24 immunofluorescent staining technique was employed to determine the coexpression of DT tumor cells. The DT hepa 1-6 and DT SMCC-1 tumor cells were washed with precooled phosphate-buffered saline and incubated on ice for 45 minutes with both phycoerythrin-labeled anti-MHC class I and FITC-labeled anti-B7.1 mAbs. Expression of MHC class I (red fluorescence) and B7.1 (green fluorescence) was determined using a FACScan, and at least 5000 cells from each sample were analyzed. The results presented in (b) were obtained from six different DT clones that have a similar pattern of the expression of MHC class I and B7.1 molecules.
RESULTS
Expression of MHC, B7, and adhesion molecules on transfectants Both parental hepa 1-6 and SMCC-1 cell lines expressed low levels of ICAM-1 and were devoid of MHC class I, MHC class II, vascular cell adhesion molecule-1, ICAM-2, and the costimulatory B7.1 and B7.2 molecules on their cell surfaces. After complete inhibition of intracellular IGF-1 production by transfection with antisense IGF-1-expressing vector, transfected hepa 1-6 and transfected SMCC-1 cells showed expression of MHC class I molecules on their cell surfaces. The expression of MHC class I molecules on these transfectants was consistent and detectable after 60 days in culture. Cells transfected with the recombinant retrovirus containing the B7.1 insert showed a high level of expression of B7.1 molecules on their cell surfaces (Fig  1a) . Expression of both MHC class I and B7.1 molecules on cell surfaces was observed in both hepa 1-6 and SMCC-1 cells that had been doubly transfected with genes encoding antisense IGF-1 and B7.1 molecules (Fig  1b) . Other adhesive and accessory molecules that were investigated in this experiment did not change significantly from before to after gene transfection. (Table 1 ). The control tumor cells transfected with mock vectors maintained a similar proliferating capability compared with parental tumor cells in the absence of IGF-1 in culture medium. To determine whether the transfectants maintain tumorigenicity in vivo, 1 ϫ 10 6 parental or transfected cells were injected s.c. into groups of nude, SCID, or C57BL/6 mice. Animals were routinely observed for visible tumor growth. As shown in Table 2 , DT SMCC-1 and DT hepa 1-6 cells lost tumorigenicity in syngeneic animals. However, these double transfectants were still able to grow and developed tumors in both nude and SCID mice. C57BL/6 mice injected with DT SMCC-1 or DT hepa 1-6 cells remained tumor-free for 120 days as determined by histopathological examination. In contrast, IGF-1 antisense or B7.1 transfectants or the control mock vector transfectants developed tumors in nude, SCID, and syngeneic C57BL/6 mice ( Table 2 ). All mice inoculated with parental tumor cells or control transfectants died within 50 days after injection with tumor cells.
Prevention and cure of established tumors by inoculation with double transfectants
To determine whether the loss of tumorigenicity of the double transfectants in syngeneic animals is associated with the generation of an antitumoral immune response, groups of C57BL/6 mice were injected s.c. either with 1 ϫ 10 6 DT SMCC-1 or 1 ϫ 10 6 DT hepa 1-6 cells or with the same dose of MT cells (MT SMCC-1 or MT hepa 1-6). After 2 weeks, mice were challenged s.c. with 1 ϫ 10 6 parental SMCC-1 or 1 ϫ 10 6 hepa 1-6 cells, respectively. All mice immunized with double transfectants became resistant to parental tumor challenge. Mice immunized with either DT SMCC-1 or DT hepa 1-6 cells remained tumor-free for Ͼ120 days after challenge with the respective parental tumor cells. In contrast, animals immunized with mock transfectants and challenged with parental tumor cells all died with huge tumor burdens within 45 days after parental tumor challenge (Fig 2, a and b) . The immunity elicited by injection of DT SMCC-1 and DT hepa 1-6 cells was tumor-specific. Animals immunized with DT SMCC-1 cells did not support growth of parental SMCC-1 cells, but still formed tumors after challenge with wild-type (wt) hepa 1-6 cells (Fig 2c) . Similar results were obtained in mice immunized with DT hepa 1-6 cells when challenged with wt SMCC-1 cells (Fig 2d) . Immunization with the double transfectants also effectively eradicated established tumors. Mice were inoculated s.c. with (Table 3) . ␥-irradiated DT tumor cells maintained ability to stimulate naive spleen cells and to generate CTLs in vitro as well as to elicit antitumoral therapeutic responses in vivo.
Generation and characterization of tumor-specific CTLs both in vitro and in vivo
To investigate the ability of DT transfectants to prime naive spleen cells with the generation of tumor-specific CTLs in vitro, splenocytes from C57BL/6 mice were cocultured with double transfectants or with transfectants used as a control in the presence of rIL-2 in vitro. Cytotoxicity toward autologous tumor cells was observed only in spleen cells cocultured with double transfectants. The CTLs induced in this system were CD3 ϩ CD8 ϩ T cells, as demonstrated by immunofluorescent staining and flow cytometry analysis. The lysis of 51 Cr-labeled SMCC-1 cells (Fig 3a) or hepa 1-6 cells (Fig 3b) was highly specific. Syngeneic or allogeneic tumor cells or NK-sensitive YAC-1 cells were not affected, and no cytolytic activity was detected in the coculture with mock virus transfectants. Antitumoral specific CTL activity was also detectable in spleen cells freshly prepared from tumor-bearing mice immunized with double transfectants (Fig 3c) . This cytotoxic killing activity was greatly enhanced when the spleen cells were cocultured with identical double transfectants in vitro (Fig 3d) . Addition of anti-MHC class I mAb into the effector to target coculture completely blocked the cytolytic activity to the background level, further demonstrating that the CTLs generated were MHC class I-restricted. TCR repertoire analysis of the CTLs generated both in vitro and in vivo using a panel of mAbs specific for mouse TCR V␤ chain showed a heterogeneous TCR V␤ usage (data not shown).
Therapeutic cure of established tumors by adoptive CTL transfer
To determine the efficacy of CTLs generated in vitro by priming naive spleen cells with DT cells for the treatment of established tumors, CTLs were adoptively transferred into mice bearing hepa 1-6 hepatoma or SMCC-1 colon carcinoma at a dose of 1 ϫ 10 7 cells. This was followed by i.v. injection of 1000 U of human rIL-2 daily for 10 days. As anticipated, 9 of 12 mice treated with CTLs generated by stimulating spleen T cells with DT SMCC-1 showed complete tumor regression within a 4-week period and survived for 120 days without tumor recurrence. Three mice had slow tumor growth and died at 75, 85, and 86 days after tumor inoculation. A similar result was obtained in the hepa 1-6 hepatoma model system (Table 4 ). Mice injected with control spleen cells were stimulated in vitro with respective mock virustransfected tumor cells under a procedure similar to that described above, in combination with i.v. administration of rIL-2 at the same dosage; all of these mice developed tumors and died within 51 days after tumor inoculation.
DISCUSSION
We demonstrated previously that transfection of rat and mouse hepatoma, glioblastoma, and teratocarcinoma cells expressing high levels of IGF-1 and deficient costimulatory molecules with an episomal-based vector expressing IGF-1 antisense RNA significantly inhibited growth and proliferation in vitro. In addition, this treatment abolished tumorigenicity in syngeneic animals. [5] [6] [7] [8] [9] [10] [11] [12] Immunization with the IGF-1 antisense transfectants elicited effective antitumoral immune responses that were both preventive and curative. 7, 8 More recently, similar results have been reported by several groups, demonstrating that blockage of IGF-1 receptor with an antisense approach could convert tumor cells to an immunogenic phenotype. 9 -11 Significant inhibition of cell proliferation in vitro was also observed in tumor cells after transfection with the IGF-1 antisense gene. The decrease in cell proliferation is reversible and can be overcome in the presence of exogenous IGF-1 in culture. In addition, both parental and transfected cells showed similar growth rates in nude and SCID mice, in which host IGF-1 normally persists. Therefore, the immunoge- nicity induced by transfection with IGF-1 antisense gene into tumor cells is not due to the decreased proliferation and growth in vitro. The mechanism(s) by which the antitumoral immunity is elicited by this IGF-1 antisense approach remains to be elucidated. It has been reported recently that the enhanced immunogenicity of tumor cells transfected with IGF-1 antisense cDNA is associated with increased expression of MHC class I Ag and other accessory molecules on the transfected cell surfaces. 12 Our result seems consistent with recent findings that tumor cells may down-regulate the expression of MHC class I on cell surfaces to avoid immunosurveillance; restoration of the expression of MHC class I Ag on tumor cells by gene transfection and other approaches may therefore convert poorly immunogenic tumors to immunogenic ones. 30, 31 The IGF-1 antisense approach is not uniformly effective in generating immunogenic tumor cells in all types of tumors, as demonstrated by the tumorigenicity in syngeneic animals and by the inability to induce protective immunity against parental tumor cell challenges.
Mouse hepa 1-6 hepatoma and SMCC-1 colon carcinoma are two poorly immunogenic tumor cell lines, as shown with B7 gene transfection experiments. 24 Transfection of these two cell lines with IGF-1 antisense cDNA greatly enhanced the expression of MHC class I molecules on tumor cell surfaces. However, transfected hepa 1-6 or SMCC-1 cells with complete inhibition in the production of IGF-1 and expressing high levels of MHC class I Ag on cell surfaces remained unable to produce antitumoral immunity in vitro or in vivo. Here, we report that cotransfection of IGF-1 antisense and B7.1 genes renders hepa 1-6 and SMCC-1 tumor cells more immunogenic. The DT tumor cells are effective in stimulating naive T cells in vitro with the generation of CTLs and are able to act as cellular tumor vaccines to elicit antitumoral immune responses that eradicate established tumors in vivo. Down-regulation of MHC class I expression on rat thyroid tumor cells has been reported to occur through the action of IGF-1. 32 Neutralizing IGF-1 with Ab fails to restore MHC class I expression or make the cells immunogenic. In addition to enhancing the expression of MHC class I molecules on cell surfaces, transfection with IGF-1 antisense cDNA may directly enhance Ag processing and presentation by tumor cells and may lead to the production of cytokines or chemokines that are essential for T-cell activation. 7, 8, 12 IGF-1 antisense gene transfer may fail to covert hepa 1-6 and SMCC-1 tumor cells into immunogenic ones. One reason is that enhanced Ag-specific signaling mediated by tumor Ag/MHC complexes on IGF-1 antisense transfectants may be below the threshold critical for activation of T cells. The expression of ϩ T cells appear to be less important for the induction of immunity in these model systems. Our results further support those obtained in studies of glioblastoma, melanoma, and hepatoma, which indicated that tumor cells transfected either with the IGF-1 antisense or with the B7 gene can directly stimulate naive T cells without the participation of CD4 ϩ T cells. 6, 8, 14, 17 The tumor-specific antitumoral immunity can be adoptively transferred into naive animals by i.v. injection of CTLs generated either in vitro or in vivo. TCR repertoire analysis of these CTLs with a panel of mAbs specific for the mouse TCR V␤ chain showed a heterogeneous TCR V␤ usage. The nature of the Ags recognized by the CTLs is under investigation. Recent reports demonstrate that human bone marrow-derived dendritic cells efficiently present Ag from apoptotic cells through the MHC class I pathway, stimulating class I-restricted CD8 ϩ CTLs. 33 Further experiments are needed to elucidate whether Ag-processing cells are involved in the induction of antitumoral immunity in vivo in these model systems.
Our results demonstrate that strongly immunogenic tumor cells can be generated by the in vitro cotransfection of low or nonimmunogenic tumor cells with vectors inserted with genes encoding IGF-1 antisense and B7.1 molecules. In addition to the potential clinical application of the DT tumor cells as cellular cancer vaccines, this approach may also be effective in generating tumorspecific CTLs for adoptive immunotherapy. Thus, immunization with the autologous cellular vaccines generated by this double gene transfection approach may provide a strategy for cancer immunotherapy. 
